Tags

Type your tag names separated by a space and hit enter

Primary aldosteronism - treatment options.
Growth Horm IGF Res. 2003 Aug; 13 Suppl A:S102-8.GH

Abstract

Diagnosis of primary aldosteronism results in either the surgical cure of hypertension or targeted pharmacotherapy. The two major subtypes of primary aldosteronism are unilateral aldosterone-producing adenoma (APA) and bilateral idiopathic hyperaldosteronism (IHA). Patients with APA usually are treated with unilateral adrenalectomy and patients with IHA are treated medically. The majority of patients with primary aldosteronism have the IHA subtype and require pharmacotherapy. Spironolactone has been the drug of choice to treat primary aldosteronism. However, it is not selective for the aldosterone receptor, and side effects include gynecomastia, erectile dysfunction and menstrual irregularity. Eplerenone is a new competitive and selective aldosterone receptor antagonist recently approved by the United States Food and Drug Administration for the treatment of hypertension. It lacks the side effects associated with spironolactone and will be the superior drug if it is shown to be as effective as spironolactone for the treatment of mineralocorticoid-dependent hypertension.

Authors+Show Affiliations

Divisions of Endocrinology, Metabolism, Nutrition and Internal Medicine, Mayo Medical School, Mayo Clinic and Mayo Foundation, 200 First Street S.W., Rochester, MN 55905, USA. young.william@mayo.edu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12914736

Citation

Young, William F.. "Primary Aldosteronism - Treatment Options." Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society, vol. 13 Suppl A, 2003, pp. S102-8.
Young WF. Primary aldosteronism - treatment options. Growth Horm IGF Res. 2003;13 Suppl A:S102-8.
Young, W. F. (2003). Primary aldosteronism - treatment options. Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society, 13 Suppl A, S102-8.
Young WF. Primary Aldosteronism - Treatment Options. Growth Horm IGF Res. 2003;13 Suppl A:S102-8. PubMed PMID: 12914736.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Primary aldosteronism - treatment options. A1 - Young,William F,Jr PY - 2003/8/14/pubmed PY - 2004/5/14/medline PY - 2003/8/14/entrez SP - S102 EP - 8 JF - Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society JO - Growth Horm IGF Res VL - 13 Suppl A N2 - Diagnosis of primary aldosteronism results in either the surgical cure of hypertension or targeted pharmacotherapy. The two major subtypes of primary aldosteronism are unilateral aldosterone-producing adenoma (APA) and bilateral idiopathic hyperaldosteronism (IHA). Patients with APA usually are treated with unilateral adrenalectomy and patients with IHA are treated medically. The majority of patients with primary aldosteronism have the IHA subtype and require pharmacotherapy. Spironolactone has been the drug of choice to treat primary aldosteronism. However, it is not selective for the aldosterone receptor, and side effects include gynecomastia, erectile dysfunction and menstrual irregularity. Eplerenone is a new competitive and selective aldosterone receptor antagonist recently approved by the United States Food and Drug Administration for the treatment of hypertension. It lacks the side effects associated with spironolactone and will be the superior drug if it is shown to be as effective as spironolactone for the treatment of mineralocorticoid-dependent hypertension. SN - 1096-6374 UR - https://www.unboundmedicine.com/medline/citation/12914736/Primary_aldosteronism___treatment_options_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1096637403000649 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.